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Abstract
 
We describe a metabolic defect in bile acid synthesis involv-
ing a deficiency in 7
 
a
 
-hydroxylation due to a mutation in
the gene for the microsomal oxysterol 7
 
a
 
-hydroxylase en-
zyme, active in the acidic pathway for bile acid synthesis.
The defect, identified in a 10-wk-old boy presenting with se-
vere cholestasis, cirrhosis, and liver synthetic failure, was
established by fast atom bombardment ionization-mass
spectrometry, which revealed elevated urinary bile acid ex-
cretion, a mass spectrum with intense ions at 
 
m/z
 
 453 and
 
m/z
 
 510 corresponding to sulfate and glycosulfate conju-
gates of unsaturated monohydroxy-cholenoic acids, and an
absence of primary bile acids. Gas chromatography-mass
spectrometric analysis confirmed the major products of he-
patic synthesis to be 3
 
b
 
-hydroxy-5-cholenoic and 3
 
b
 
-hydroxy-
5-cholestenoic acids, which accounted for 96% of the total
serum bile acids. Levels of 27-hydroxycholesterol were 
 
. 
 
4,500
times normal. The biochemical findings were consistent
with a deficiency in 7
 
a
 
-hydroxylation, leading to the accu-
mulation of hepatotoxic unsaturated monohydroxy bile ac-
ids. Hepatic microsomal oxysterol 7
 
a
 
-hydroxylase activity
was undetectable in the patient. Gene analysis revealed a
cytosine to thymidine transition mutation in exon 5 that
converts an arginine codon at position 388 to a stop codon.
The truncated protein was inactive when expressed in 293
cells. These findings indicate the quantitative importance of
the acidic pathway in early life in humans and define a fur-
ther inborn error in bile acid synthesis as a metabolic cause
of severe cholestatic liver disease. (
 
J. Clin. Invest. 
 
1998. 102:
1690—1703.) Key words: cholestasis 
 
¥
 
 mass spectrometry 
 
¥
 
 ge-
netics 
 
¥
 
 cholesterol metabolism
 
Introduction
 
Inborn errors in bile acid synthesis are now a recognized cate-
gory of metabolic liver disease (1, 2). Specific defects have
been identified in the enzymes catalyzing reactions responsible
for changes to the steroid nucleus (3, 4) and side chain (5—9)
of cholesterol and its intermediates in the pathway leading to
the formation of cholic and chenodeoxycholic acids (10).
These familial conditions are clinically manifest as syndromes
of progressive cholestatic liver disease, neurological disease,
and fat-soluble vitamin malabsorption (1, 2). Early diagnosis is
important because patients with these disorders can be suc-
cessfully treated by oral administration of cholic acid; normal-
ization in serum liver enzymes and bilirubin and resolution of
the histologic lesion are consistent responses to bile acid ther-
apy (1, 2, 11, 12), and the need for liver transplantation in most
cases can be circumvented.
Recognition of defects in bile acid synthesis has relied upon
mass spectrometric analysis of the urine and serum to establish
an absence or marked reduction in synthesis of the normal pri-
mary bile acids, cholic and chenodeoxycholic acids, concomi-
tant with the presence of excessive amounts of atypical bile ac-
ids and sterols that are synthesized as a consequence of the
enzyme deficiency (13). There has been relatively little success
in understanding the genetic basis and molecular biology of
these disorders, because with few exceptions the genes respon-
sible for most of these enzymes have yet to be identified, se-
quenced, and cloned (10).
The synthesis of primary bile acids from cholesterol occurs
via two pathways: the classical neutral pathway involving cho-
lesterol 7
 
a
 
-hydroxylase and the acidic pathway, which uses a
distinct microsomal oxysterol 7
 
a
 
-hydroxylase (14—20). The ex-
pression of the oxysterol 7
 
a
 
-hydroxylase, and hence acidic
pathway, is developmentally regulated in mice (21, 22). When
active, this pathway partially compensates for the neutral path-
way in animals lacking the cholesterol 7
 
a
 
-hydroxylase gene
(21), a finding that indicates the quantitative importance of the
acidic pathway for bile acid synthesis. The quantitative contri-
bution of these two pathways to total bile acid synthesis has
also been measured in the rat (20) and the results reinforce the
view that the acidic pathway, at least in rodents, is a major
pathway for bile acid synthesis in the face of reduced choles-
terol 7
 
a
 
-hydroxylase activity.
We now describe for the first time in a human a metabolic
defect in bile acid synthesis involving a deficiency in 7
 
a
 
-
hydroxylation that represents a further cause of severe neona-
tal cholestatic liver disease. The biochemical presentation of
this new inborn error features almost exclusively the formation
of highly cholestatic and hepatotoxic monohydroxy-bile acids
with a 3
 
b
 
-hydroxy-
 
D
 
5
 
 ring structure. Molecular studies estab-
lish this defect to be due to mutation of the oxysterol 7
 
a
 
-hydrox-
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ylase gene (symbol 
 
CYP7B1
 
). These findings highlight the
quantitative importance of the acidic pathway for bile acid syn-
thesis in early human life.
 
Methods
 
Clinical history of patient JC
 
The patient was a Hispanic male infant born at term after an unevent-
ful pregnancy by a vaginal delivery with a birth weight of 7 lb. 12 oz.
(3.52 kg). The patientÕs parents were first cousins, both from the same
small village in Mexico. This was the second pregnancy; the first re-
sulted in a healthy male infant who was 2.5 yr of age at the time the
proband presented. The patient developed jaundice at 6 d of age (to-
tal serum bilirubin 18.6 mg/dl), which resolved with phototherapy.
During week 6 of life he intermittently passed acholic stools; jaundice
returned at 8 wk of age. At 10 wk of age, bright red blood was passed
per rectum and a spontaneous episode of epistaxis occurred. The pa-
tient was then referred to the ChildrenÕs Hospital in Denver for eval-
uation. On physical examination, the patient was alert and icteric
with height and weight between the 25th and 50th percentiles. A right
scleral hemorrhage was present and nares were crusted with blood,
but not actively bleeding. There were no dysmorphic features or car-
diac murmur, and neurological examination was normal. The liver
was firm and 3 cm below the right costal margin and the spleen tip
was palpable. Ascites, spider hemangiomata, bruising, and edema
were absent.
Initial laboratory studies revealed serum AST 440 IU/liter (nor-
mal 20—60), ALT 160 IU/liter (normal 7—46), alkaline phosphatase
1,384 IU/liter (normal 110—460), total/direct bilirubin 8.4/4.8 mg/dl
(normal 
 
, 
 
1.0), prothrombin time 41 s (normal 12.4—14.4), and blood
ammonia 37 
 
m
 
mol/liter (normal 29—57). Serum GGT was 14 IU/liter,
cholesterol was 101 mg/dl, and CBC was normal. Evaluations for viral
infections, alpha-1-antitrypsin deficiency, hereditary tyrosinemia, cys-
tic fibrosis, hypopituitarism, and iron storage disease were normal or
negative. Serum 
 
a
 
-tocopherol concentration was 5.5 
 
m
 
g/ml (normal
3.8—15.5), 
 
a
 
-tocopherol: total serum lipids ratio was 1.07 (normal
 
. 
 
0.6 mg/g), serum retinol 6.0 
 
m
 
g/dl (normal 19—77), and retinol bind-
ing protein was 0.7 mg/dl (normal 1.0—5.0). Abdominal ultrasonogra-
phy showed a small gallbladder, no choledochal cyst, no dilatation of
bile ducts, and bilateral enlarged kidneys without hydronephrosis.
Hepatobiliary scintigraphy with iminodiacetic acid showed delayed
hepatic clearance and no biliary excretion. Parenteral vitamin K
treatment led to a substantial reduction in the prothrombin time to
19.1 s. Percutaneous liver biopsy (see Results) performed after cor-
rection of coagulopathy suggested biliary tract obstruction. The pa-
tient then underwent an exploratory laparotomy which showed an
enlarged, firm, green liver, a normal gallbladder containing yellow
bile, and a normal biliary system was seen on an intraoperative chol-
angiogram performed through the gallbladder. Urine and serum were
shipped to Cincinnati for evaluation of bile acid synthetic defects.
The patient was treated with a medium chain triglyceride-con-
taining formula, fat-soluble vitamin supplementation (phytonadione,
25-hydroxy-vitamin D, 
 
D
 
-
 
a
 
-tocopheryl PEG-1000 succinate), and ur-
sodeoxycholic acid (UDCA)
 
1
 
 at 15 mg/kg body wt/d (Fig. 1). UDCA
therapy was terminated after 10 d because of a marked increase in se-
rum bilirubin and aminotransferases. After the recognition of a de-
fect in primary bile acid synthesis, the patient was then treated with
oral cholic acid at 15 mg/kg body wt/d. There was no clinical response
after 49 d of cholic acid therapy with continued deterioration of he-
patic synthetic function (Fig. 1). Because of poor weight gain, pro-
gressive hepatosplenomegaly, hypoalbuminemia, and coagulopathy,
the patient underwent orthotopic liver transplantation from a ca-
daver donor at 4.5 mo of age. Immunosuppression included cyclospo-
rine, corticosteroids, and azathioprine. Acute allograft rejection oc-
curred on day 9 after transplant and responded to large intravenous
corticosteroid bolus therapy. Neutropenia developed on day 10 and
was followed by 
 
Pseudomonas aeruginosa
 
 sepsis and ecthyma gan-
grenosum of the buttocks on day 15. The patient responded well to
intravenous antibiotic therapy and a reduction of immunosuppres-
sion; however, on day 19 he developed sudden, rapidly progressive
cerebral edema and died 24 h later. Autopsy revealed disseminated
lymphoproliferative disease (Epstein-Barr virus—related) in all body
tissues, including brain and liver, and mild allograft rejection.
During cholic acid therapy, urine and serum specimens were ob-
tained for analytical studies of bile acid metabolites. At the time of
liver transplantation, the diseased liver and bile were snap-frozen for
analytical studies. DNA was prepared from peripheral white blood
cells from the patient and his mother and father.
 
Qualitative and quantitative bile acid analysis
 
Total and individual bile acids were measured in urine, serum, bile, and
liver tissue from the patient using a combination of fast atom bombard-
ment ionization-mass spectrometry (FAB-MS) and gas chromato-
graphy-mass spectrometry (GC-MS) as described elsewhere (23—25).
 
1. 
 
Abbreviations used in this paper:
 
 
 
D
 
5
 
, unsaturation (double bond) in
the molecule at the carbon position designated by the superscript, i.e.,
5-ene; FAB-MS, fast atom bombardment ionization-mass spectrome-
try; GC-MS, gas chromatography-mass spectrometry; Me-TMS,
methyl ester-trimethylsilyl; MU, methylene unit; UDCA, urso-
deoxycholic acid.
Figure 1. Changes in serum concentrations of AST, ALT, direct 
bilirubin, albumin, and prothrombin time in patient JC during ther-
apy with UDCA (15 mg/kg body wt/d) and cholic acid (15 mg/kg 
body wt/d), up until the time of liver transplantation at 9 wk after pre-
sentation. Initial elevated prothrombin time responded to parenteral 
vitamin K injection. Fat-soluble vitamin supplementation was contin-
ued throughout the patientÕs course (see text).
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Solid-phase extraction of bile acids from urine, serum, and bile.
 
The internal standard, nordeoxycholic acid (1—10 
 
m
 
g), was added to
samples of urine (5—10 ml), bile (100 
 
m
 
l), and serum (0.5—1.0 ml), and
bile acids were extracted by liquid-solid extraction using reverse-
phase octadecylsilane-bonded silica cartridges (Bond Elut-C
 
18
 
; Ana-
lytichem Inc., Harbor City, CA) (26, 27). The cartridge was washed
with water, and bile acids and their conjugates were recovered from
the cartridge by elution with methanol (5 ml).
 
Extraction of bile acids from liver tissue.
 
A small sample of liver
(150 mg) obtained from the patient at the time of liver transplanta-
tion was ground to a fine paste in distilled water (20 ml) and brought
to a final concentration of 80% methanol (100 ml). The sample was
sonicated for 30 min, and then refluxed for 2 h and filtered (28). The
residue was resuspended in 100 ml of chloroform/methanol (1:1, vol/
vol), refluxed for 1 h, and filtered. The combined extracts were taken
to dryness on a rotary evaporator. The dried extract was resuspended
in 80% methanol (1 ml) by sonication, and the internal standard, nor-
deoxycholic acid (5 
 
m
 
g) was added. The sample was diluted with 0.01 M
acetic acid (19 ml) and passed through a column of Lipidex 1000 (bed
size 4 
 
3
 
 1 cm; Packard Instrument Co., Groningen, The Nether-
lands). Aqueous acetic acid (20 ml) was passed through the gel bed,
followed by distilled water (20 ml), and the combined effluent and
washings were then passed through a Bond Elut-C
 
18
 
 cartridge and
discarded. Bile acids were recovered by elution of the Lipidex 1000
column and the Bond Elut-C
 
18
 
 cartridge with methanol, 20 and 5 ml,
respectively, and the combined extracts were taken to dryness.
 
Solvolysis, hydrolysis, ion-exchange chromatography, and deriva-
tization steps.
 
The methanolic extracts from the urine, serum, bile,
and liver tissue were taken to dryness under a stream of nitrogen, and
bile acid conjugates were solvolyzed (29) and enzymically hydrolyzed
(30). After hydrolysis, bile acids were then extracted on a Bond Elut-
C
 
18
 
 cartridge and the unconjugated bile acids were isolated by lipo-
philic anion exchange chromatography on a column (bed size 0.6 g) of
diethylaminohydroxypropyl Sephadex LH-20 (Lipidex DEAP; Pack-
ard Instrument Co.) prepared in 72% ethanol and converted to the
acetate form (31). Unconjugated bile acids were eluted with 0.1 mol/
liter acetic acid in 72% ethanol (7 ml), and converted to volatile methyl
ester-trimethylsilyl (Me-TMS) ether derivatives (32) for analysis by
GC-MS operated in repetitive scanning mode.
 
Urinary bile acid analysis by FAB-MS.
 
Negative ion FAB-MS
spectra of bile acid conjugates excreted in urine were obtained after
placing 1 
 
m
 
l of the methanolic extract of urine before hydrolysis of
conjugates (equivalent to 20 
 
m
 
l of the urine) onto a drop of a glycerol/
methanol (1:1, by vol) matrix spotted on a stainless steel probe. The
probe was introduced into the ion source of a VG Autospec Q mass
spectrometer (Fisons Instruments, Manchester, UK) and ionized by a
beam of fast atoms of cesium (35 keV) fired at the target containing
the sample. Negative ion mass spectra were recorded over the mass
range of 50—1,000 D.
 
GC-MS.
 
Bile acid Me-TMS ethers were separated on a 30 m 
 
3
 
0.25 mm i.d. DB-1 capillary column using temperature programmed
operation from 225 to 295
 
8
 
C with increments of 2
 
8
 
C/min, after initial
and final isothermal periods of 2 and 20 min, respectively. GC-MS
was performed on a VG Autospec Q mass spectrometer operated in
electron ionization (70 eV) mode. Repetitive scanning was performed
over the mass range of 50—800 D. The identification of a bile acid was
based on its GC retention index from both the scan number and time,
and ion current response at its characteristic mass (33). Bile acid con-
centrations in urine, serum, bile, and liver tissue were quantified by
gas chromatography by comparing the peak height response with the
response obtained for a known amount of the added internal stan-
dard, nordeoxycholic acid (23, 34).
 
Biochemical enzyme assays
 
Microsomal membranes were prepared from frozen human liver fol-
lowing a standard protocol of sequential centrifugation. Aliquots of
liver tissue were Dounce-homogenized in 4 vol of ice-cold sucrose
buffer (0.25 M sucrose, 1 mM EDTA, 20 mM Tris-Cl, pH 7.4, 9,000
trypsin IU/ml aprotinin, 10 
 
m
 
g/ml pepstatin, and 5 
 
m
 
M phenylmethyl-
sulfonyl fluoride). The homogenate was centrifuged for 10 min at 600 
 
g
 
,
the supernatant was transferred to fresh tubes and centrifuged for 15
min at 10,000 
 
g
 
. The supernatant from this step was centrifuged for 30
min at 130,000 
 
g
 
. Membrane pellets from the final centrifugation step
were resuspended by homogenization in 50 mM Tris-acetate (pH
7.4), 20% (vol/vol) glycerol, 1 mM EDTA. Protein concentrations were
determined using the BCA protein assay kit (Pierce, Rockford, IL).
Cholesterol 7
 
a
 
-hydroxylase activity was assayed in the presence
of 7 nmol of [
 
14
 
C]cholesterol (56 mCi/mmol) in 0.5 ml containing 50
mM Tris-acetate (pH 7.4), 20% (vol/vol) glycerol, 1 mM EDTA, 2
mM dithiothreitol, 0.06% Triton X-100, 1.5 mM NADPH, and 1 mg
of microsomal protein. Reactions were carried out for 30 min at 37
 
8
 
C,
followed by extraction with methylene chloride. The organic phase
was taken to dryness under a stream of nitrogen gas. Lipids were re-
dissolved in 50 
 
m
 
l Folch reagent (chloroform/methanol 2:1 by vol)
and subjected to thin layer chromatography in ethyl acetate/toluene
(2:3 by vol). Radiolabeled products were quantified using a System
200 Imaging Scanner (Bioscan Inc., Washington, DC). For determina-
tion of oxysterol 7
 
a
 
-hydroxylase activity, 0.06 nmol [
 
3
 
H]25-hydroxy-
cholesterol (80 Ci/mmol) was incubated with 250 
 
m
 
g of microsomal
protein using the assay described above. Steroid 5
 
a
 
-reductase type 1
activity was measured under the same conditions except that [
 
14
 
C]tes-
tosterone (58 mCi/mmol, final concentration 14 
 
m
 
M) was used as a
substrate and the silica gel plates were developed in a solvent system
containing chloroform/ethyl acetate (3:1 by vol). The detection limits
for these enzymatic activities were 0.05—0.25 pmol/min/mg cell pro-
tein for oxysterol 7
 
a
 
-hydroxylase and steroid 5
 
a
 
-reductase and 0.5—
2.0 pmol/min/mg cell protein for cholesterol 7
 
a
 
-hydroxylase.
 
Genetic analysis
 
cDNA and genomic clones encoding the human oxysterol 7
 
a
 
-hydrox-
ylase were isolated by hybridization screening. The exon/intron struc-
ture of the gene was deduced by DNA sequence analysis and compar-
ison to the cDNA sequence. Chromosomal localizations of the
oxysterol 7
 
a
 
-hydroxylase and cholesterol 7
 
a
 
-hydroxylase genes were
performed using the Stanford G3 panel of radiation hybrid DNAs
(Research Genetics, Huntsville, AL) and PCR. A mutation in the oxy-
sterol 7
 
a
 
-hydroxylase gene was identified by amplification of individ-
ual exons followed by DNA sequence analysis. The DNA sequence
of the oligonucleotide primers and the thermocycler programs used
to amplify exons are available upon request (D.W. Russell).
 
cDNA expression
 
Cultured monolayers of human embryonic 293 cells or Chinese hamster
ovary cells were transfected using an MBS kit (Stratagene, La Jolla,
CA). Oxysterol 7
 
a
 
-hydroxylase enzyme activity was measured 24 h
after transfection by the addition of 0.2 mM [
 
3
 
H]25-hydroxycholesterol
to the culture media (22). After the indicated times of incubation, ste-
rols were extracted from the media and analyzed by thin layer chroma-
tography on silica plates. Activity was quantified by phosphorimaging.
Experiments using 293 cells were carried out in the presence of 50 mM
nafimidone to inhibit an endogenous oxysterol 7
 
a
 
-hydroxylase enzyme
activity (22). Oxysterol 7
 
a
 
-hydroxylase protein levels were estimated by
immunoblotting as described elsewhere (22). Site-directed mutagenesis
was performed using PCR. All modified cDNAs were subjected to
DNA sequence analysis to confirm the absence of spurious mutations.
 
Results
 
Pathology
 
The initial liver biopsy (day 75 of life) showed a marked in-
crease in portal connective tissue with bridging fibrosis and
probable cirrhosis (Fig. 2 
 
A
 
). There was mild portal inflamma-
tion mixed with residual extramedullary hematopoiesis, canalic-
ular and bile duct bile plugging, and moderate lobular disarray
with giant cell transformation (Fig. 2 
 
B
 
). Prominent bile duct
 Oxysterol 7
 
a
 
-Hydroxylase Deficiency
 
1693
 
proliferation was also noted suggesting an obstructive etiology
(Fig. 2 
 
C
 
). No hepatocyte drop out, viral cytopathic changes,
pseudoacinar change, evidence of alpha-1-antitrypsin disease,
or obvious steatosis was seen.
At time of laparotomy (day 77 of life), a wedge liver biopsy
was performed and showed findings identical to the needle bi-
opsy; cirrhosis was confirmed with regenerative nodules seen.
Ultrastructural evaluation showed enlarged and often multinu-
cleated hepatocytes containing cytoplasmic bile. Canalicular
bile did not have the appearance of that seen in BylerÕs dis-
ease. The mitochondria were normal in appearance and perox-
isomes appeared increased in number but no structural abnor-
malities were identified. No metabolic storage product or viral
particles were seen.
The explanted liver (day 137 of life) showed identical
findings although there appeared to be hepatocytic damage
due to the accumulating bile with occasional necrotic hepato-
cytes and patchy chronic inflammation seen (Fig. 2 
 
D
 
). Other
than bile duct proliferation and bile plugging, the ducts ap-
peared histologically normal, as did the gallbladder.
The posttransplant liver biopsy (day 149 of life) showed
changes of moderate acute rejection with portal expansion by
mononuclear inflammatory cells with bile duct involvement
and portal and central vein endothelialitis. No bile plugging,
cholestasis, or hepatocyte drop out was seen. Subsequent liver
biopsy (day 151 of life) showed resolution of findings of rejec-
tion. After the onset of sepsis, a bone marrow biopsy was done
to evaluate pancytopenia and showed left-shifted maturation
but no evidence of significant hemophagocytosis or other ab-
normalities was seen.
Figure 2. (A) Needle biopsy ob-
tained at day 75 of life showing 
extensive portal fibrosis with 
nodules, and portal inflamma-
tion mixed with extramedullary 
hematopoiesis (trichrome, origi-
nal magnification 340). (B) 
Higher power view of same bi-
opsy showing multinucleated gi-
ant cell transformation (arrow-
heads) and canalicular bile stasis 
(arrow). The portal tract inflam-
mation and fibrosis are also 
demonstrated (hematoxylin and 
eosin, original magnification 
3200). (C) Wedge biopsy of 
liver obtained at day 77 of life 
showing similar findings with 
bile duct proliferation (arrow-
heads) and portal fibrosis high-
lighted (trichrome, original mag-
nification 3200). (D) Explanted 
liver, day 137 of life, showing re-
generative nodules and exten-
sive fibrosis (trichrome, original 
magnification 3100).
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At autopsy (day 158) the large perineal ulcer with bacterial
overgrowth was seen and felt to be the source of sepsis. There
was third space fluid accumulation and an extensive lympho-
histiocytic proliferative process involving the bone marrow,
spleen, epicardium, meninges, and other soft tissues. The his-
tology was that of Epstein-Barr virus—induced lymphoprolifer-
ative disease, and was confirmed by Eber in situ hybridization
and PCR amplification. There was renomegaly with the kid-
neys weighing 
 
z
 
 2.5 times the expected weight and grossly and
histologically showed medullary cysts of varying sizes. This
was the only organ system involved (other than the native
liver) that may be related to the enzyme defect identified. No
other developmental defects were seen.
 
Biochemical identification of an inborn error in bile
acid synthesis
Urinary bile acid analysis.
 
The negative ion mass spectrum of
the urine from patient JC revealed a series of intense ions in
the mass range corresponding to bile acids and their conju-
gates (
 
m/z
 
 350—700) and consistent with a severe cholestatic
condition (Fig. 3). The major ions at 
 
m/z
 
 453 and 510 were con-
sistent with the pseudomolecular ions ([M-H
 
2
 
]) for the sulfate
and glycosulfate conjugates, respectively, of monohydroxy-
cholenoates (C
 
24
 
 bile acids). The ion at 
 
m/z
 
 480 represents a
corresponding taurine conjugate. Several other ions of un-
known origin were also present. None of these ions are ob-
served in mass spectra from the urine of normal infants of sim-
ilar age, which typically show mainly ions derived from the
glycerol matrix (
 
m/z
 
 367, 459, 551, and 643) (Fig. 3, 
 
top
 
). Sub-
sequent analysis of the urine from both parents by FAB-MS
was unrevealing; none of the major ions observed in the mass
spectrum of the patientÕs urine were present in the mass spec-
tra of the parentsÕ urine (data not shown), which were indistin-
guishable from normal adult urine.
GC-MS analysis of the Me-TMS ether derivatives of bile
acids isolated after solvolysis and hydrolysis of the urine sam-
ple (Fig. 4) revealed one major compound having a retention
index of 32.00 methylene units (MU). The retention index and
electron ionization (70 eV) mass spectrum of this compound
(Fig. 5) were found to be identical to that of the Me-TMS ether
of the authentic monohydroxy bile acid, 3
 
b-hydroxy-5-chole-
noic acid (33, 35—37). The molecular ion was m/z 460, and con-
sistent with a monohydroxy-unsaturated C24 bile acid. Promi-
nent ions at m/z 404 [M-56], m/z 331 [M-129], the base peak,
and m/z 129 are all induced by the presence of a C-5,C-6 dou-
ble bond in the steroid nucleus. The 129-D fragment consists
Figure 3. The negative ion FAB-MS mass spectrum (middle) of the urine sample from a 10-wk-old patient (JC) diagnosed with oxysterol 7a-
hydroxylase deficiency is compared with the corresponding mass spectrum from a normal infant of similar age (top). The mass spectrum of the 
urine from the patient after orthotopic liver transplantation (OLT) is shown in the bottom panel. Ions corresponding to the sulfate and glycosul-
fate conjugates of the monohydroxylated bile acid, 3b-hydroxy-5-cholenoic acid (m/z 453 and m/z 510, respectively), are the signature metabo-
lites for this inborn error in bile acid synthesis. The ion m/z 514 corresponds to taurine-conjugated trihydroxycholanoic acid due to the presence 
of the primary bile acid, cholic acid. This sample was obtained immediately after transplantation and reflects synthesis of cholic acid by the new 
liver and/or the washout of cholic acid that was administered to the patient in the period leading up to orthotopic liver transplantation.
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of C-1 to C-3 and 3-OTMS, while the 56-D loss involves the
same carbon atoms but lacking the C-3-OTMS group. The
ion at m/z 370 [M-90] is formed from the loss of the trimethyl-
silanol group at C-3 from the molecular ion, while the ion at
m/z 255 arises from side chain cleavage (M-[90-115]). The uri-
nary concentration of 3b-hydroxy-5-cholenoic acid was 14.0
mmol/liter and this bile acid accounted for 77.6% of the total
bile acids excreted in urine (Table I). Only trace amounts of
cholic acid and chenodeoxycholic acids were identified in the
urine. Additionally, there was no evidence for tetrahydroxy-
lated bile acids that are typically excreted by normal neonates.
Serum bile acid analysis. The GC-MS total ion current
chromatogram of the Me-TMS ether derivatives of bile acids
isolated from the serum of the patient was remarkably simi-
lar to that of the urinary profile (Fig. 4). Two prominent
peaks were present, the major one having a retention index
of 32.00 MU and an electron ionization-mass spectrum that
was identical to 3b-hydroxy-5-cholenoic acid, the major uri-
nary bile acid. An additional compound having a retention
index of 34.45 MU gave an electron ionization (70 eV) mass
spectrum with a fragmentation pattern that had many of the
features of 3b-hydroxy-5-cholenoic acid; however, the masses
of many of the ions were higher by 42 D, suggesting the addi-
tion of [-CH2-CH2-CH2] to the side chain, and consistent with
the difference in mass between a C24 and a corresponding
C27 bile acid structure. The molecular ion was at m/z 502 and
the loss of a single trimethylsilanol function, accounting for the
ion at m/z 412, confirmed a monohydroxy bile acid. Ions at m/z
446 [M-56], m/z 373 [M-129], and m/z 129 establish the pres-
ence of a 3-trimethylsiloxy-D5 structure. A C8 side chain is evi-
Figure 4. Total ion current chro-
matograms from the GC-MS 
analysis of the Me-TMS deriva-
tives isolated after solvolysis and 
hydrolysis of bile acids in the 
urine and serum from a patient 
(JC) with oxysterol 7a-hydroxy-
lase deficiency. The major com-
pounds with retention indices of 
32.00 and 34.45 MU, respec-
tively, were identified as deriva-
tives of 3b-hydroxy-5-cholenoic 
and 3b-hydroxy-5-cholestenoic 
acids.
Table I. Bile Acid Concentrations (mmol/liter or nmol/g) and Proportions (%; Shown in Parentheses) in Urine, Serum, and Liver 
Tissue from a Patient with an Oxysterol 7a-Hydroxylase Deficiency at Baseline, during Cholic Acid Therapy, and after Transplant, 
and in His Parents
3b-OH-D5-C24 3b-OH-D5-C27 CDCA CA Others Total % Mono-OH
Urine (mmol/liter)
Patient JC:
Baseline 14.0 (76.9) ND 0.4 (2.2) 1.9 (10.4) 1.9 (10.4) 18.2 76.9
Day 2 therapy 19.9 (24.8) ND 0.2 (0.2) 47.8 (59.5) 12.6 (15.7) 80.4 24.8
Day 4 therapy 5.0 (7.2) ND 0.3 (0.4) 54.1 (77.3) 10.9 (15.5) 70.3 7.1
Day 24 therapy 21.4 (6.6) ND ND 234.7 (72.0) 69.9 (21.4) 326.0 6.6
Day 45 therapy 23.9 (12.4) ND ND 152.9 (79.4) 15.9 (8.3) 192.7 12.4
After transplant 11.1 (5.6) ND 3.9 (1.9) 165.1 (82.8) 19.4 (9.7) 199.5 5.6
Parents:
Mother 1.5 (14.5) ND 0.5 (5.4) 0.3 (2.5) 7.7 (77.0) 10.0 15.0
Father 0.4 (5.9) ND 0.5 (7.8) 0.3 (4.0) 5.7 (82.6) 6.9 5.8
Serum (mmol/liter)
Patient JC:
Baseline 86.5 (72.5) 23.9 (20.0) 3.0 (2.5) 1.5 (1.3) 4.4 (3.7) 119.2 92.6
Day 2 therapy 97.1 (66.5) 20.8 (14.2) 2.9 (2.0) 21.5 (14.7) 3.8 (2.6) 146.1 80.7
Day 4 therapy 86.5 (75.0) 17.3 (14.8) 2.3 (2.0) 6.6 (5.6) 4.2 (3.6) 116.9 88.8
Day 45 therapy 66.0 (57.6) 4.2 (3.7) 2.3 (2.0) 40.5 (35.4) 1.5 (1.3) 114.5 61.3
Parents:
Mother ND ND 0.8 (19.1) 0.3 (6.9) 1.9 (44.2) 3.0 0.00
Father ND ND 2.1 (43.3) 1.2 (23.6) 0.9 (18.4) 4.2 0.00
Liver tissue (nmol/g)
Patient JC:
At transplant 17.3 (22.7) 1.5 (2.0) 1.9 (2.5) 50.1 (65.8) 5.3 (7.0) 76.1 24.7
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Figure 5. The electron (70 eV) 
ionization-mass spectra of the 
major compounds having reten-
tion indices of 32.00 MU (scan 
110), identified in the urine and 
serum as the Me-TMS derivative 
of 3b-hydroxy-5-cholenoic acid 
(top), and 34.45 MU (scan 182), 
identified in serum as 3b-hydroxy-
5-cholestenoic acid (bottom).
Figure 6. Relative proportions of bile acids in the serum and urine of 
a patient (JC) identified with oxysterol 7a-hydroxylase deficiency.
dent from the loss of 157 D which gives rise to the ion at m/z
255 (M-[90-157]); this represents the ABCD ring structure af-
ter loss of both the side chain and trimethylsiloxy group. The
ion at m/z 291 represents the intact side chain and C/D rings,
and is analogous to the corresponding fragment at m/z 249
seen in the mass spectrum of the C24 equivalent structure (Fig.
5). The mass spectrum and GC retention index of this serum
bile acid were identical to that of 3b-hydroxy-5-cholestenoic
acid (38, 39).
Total serum bile acid concentration was 114.9 mmol/liter,
which was markedly elevated (upper limit of normal 3.5 mmol/
liter) and consistent with a severe cholestatic condition (Table
I). The 3b-hydroxy-D5 bile acids collectively accounted for
96% of identifiable serum bile acids. As with urine, low con-
centrations of cholic and chenodeoxycholic acids were present
(Fig. 6).
Biliary bile acids. Bile obtained at the time of exploratory
laparotomy was analyzed by FAB-MS. The negative ion mass
spectrum showed a weak signal at m/z 453 corresponding to
3b-hydroxy-5-cholenoic acid sulfate. There was no evidence
for canalicular secretion of primary bile acids. Several promi-
nent ions were present consistent with the pseudomolecular
ions and sodium adducts of sulfate and glucuronide conjugates
of neutral sterols (data not shown). However, this fraction was
not analyzed by GC-MS.
Neutral sterols in urine and serum. The neutral sterol frac-
tions of the baseline urine and serum samples after conversion
to the trimethylsilyl ether derivatives were analyzed by GC-
MS (Fig. 7). Both chromatograms show a conspicuous and
major component that was identified from its electron ioniza-
tion-mass spectrum (Fig. 7) and retention index (34.73 MU) as
27-hydroxycholesterol. The mass spectrum of the TMS ether
showed a molecular ion at m/z 546 consistent with an unsatur-
ated dihydroxylated C27 sterol. Ions at m/z 456 [M-90] and m/z
417 [M-129] are induced by the presence of the 5-6 double
bond. The ion at m/z 129 represents a fragment consisting of
the C-1 to C-3 bond and the 3-OTMS group. The mass spec-
trum was identical to authentic 27-hydroxycholesterol and was
similar to that reported previously (40). A second prominent
dihydroxy-sterol with a retention index of 34.00 MU was defin-
itively identified as 24-hydroxycholesterol (40, 41). Its mass
spectrum (Fig. 7) revealed a molecular ion at m/z 546. Ions at
m/z 145, the base peak, m/z 159, and the loss of 43 D from the
molecular ion (m/z 503) are explained by the fragmentation
along the side chain and are induced by the presence of a
24-OTMS group. This spectrum was identical to that reported
by Gustafsson and Sjovall (40). Traces of 25-hydroxycholes-
terol were identified in serum. Several other polyhydroxylated
sterols were found in serum and urine as evidenced from their
mass spectrometric fragmentation patterns but no attempt was
made to identify their exact structures. While there was evi-
dence for cholesterol, 7a-hydroxycholesterol could not be
found in either the urine or serum, and there was no evidence
for other 7a-hydroxylated sterols in these samples. The con-
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centrations of the major oxysterols in serum and urine are
summarized in Table II.
Effect of oral bile acid therapy with cholic acid. Urine and
serum were collected on days 2, 4, 24, and 45 during the period
the patient was undergoing oral bile acid therapy with cholic
acid and before liver transplantation. The GC-MS profiles
were similar to those obtained from the baseline analyses but
with the additional presence of the exogenous cholic acid.
There was very little change in the concentrations of 3b-hydroxy-
5-cholenoic and 3b-hydroxy-5-cholestenoic acids (Fig. 8), indi-
cating that cholic acid was ineffective in downregulating en-
dogenous bile acid synthesis by feedback inhibition (42—44).
Liver tissue bile acids. Bile acids were measured by GC-
MS in a sample of liver tissue that was collected at the time of
liver transplantation when the patient was undergoing oral bile
acid therapy with cholic acid (Table I). Cholic acid was conse-
quently the principal bile acid present, accounting for 69% of
the total bile acids in the liver, and its concentration was 50
nmol/g. The concentration of 3b-hydroxy-5-cholenoic acid, the
major endogenous bile acid identified in liver tissue, was 17.3
Figure 7. Chromatographic profiles obtained by gas chromatography of the trimethylsilyl ether derivatives of the neutral sterol fractions isolated 
from the serum and urine from a patient (JC) diagnosed with oxysterol 7a-hydroxylase deficiency. Mass spectrometry confirmed 27-hydroxycho-
lesterol and 24-hydroxycholesterol (70 eV electron ionization-mass spectra of the TMS ethers shown) to be the major neutral dihydroxy-sterols, 
and there was no evidence for 7a-hydroxylated sterols in these samples.
Table II. Concentrations of the Principal Oxysterols Identified in Serum and Urine from a Patient (JC) Identified with a Genetic 
Defect in Oxysterol 7a-Hydroxylase
Concentration (nmol/liter)
Sterol Serum Normal serum values* Urineà
7a-Hydroxycholesterol Not detected 198665 Not detected
24-Hydroxycholesterol 151000 363615 3770
25-Hydroxycholesterol 15484 2262 175
27-Hydroxycholesterol 781000 586610 27600
Polyhydroxycholesterols 346700 Ñ 5550
Total oxysterols 1278700 Ñ 37095
*Normal ranges for serum concentrations reported for healthy adults are taken from van Doormaal et al. (77) and Dzeletovic et al. (79) and are similar to
values reported by others (39, 75, 76, 78). àDeterminations were made from a random spot urine sample.
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nmol/g and it accounted for 24% of the total liver tissue bile
acids. There were no other bile acids of significant concentra-
tion identified in the liver tissue.
Bile acid metabolism after liver transplantation. Bile and
urine samples were obtained from the patient immediately af-
ter transplantation. The negative ion FAB-MS spectrum of the
urine contrasts the corresponding pretransplantation spectrum
of urine (Fig. 3, bottom) in that the characteristic ions at m/z
453 and 510 for the conjugates of 3b-hydroxy-5-cholenoic acid
were absent. Ions for the primary bile acid conjugates (m/z
514, taurocholate; m/z 498, taurochenodeoxycholic; m/z 464,
glycocholate) were observed in the posttransplantation sample
and reflect the elimination of the exogenous cholic acid admin-
istered up to the time of transplantation and the newly synthe-
sized primary bile acids by the donor liver. The negative ion
FAB-MS spectrum of the bile (data not shown) indicated nor-
mal canalicular secretion of the primary bile acid conjugates
synthesized by the donor liver and no evidence for the atypical
3b-hydroxy-D5 bile acids or neutral sterols evident in fluids ob-
tained before liver transplantation.
Identification of an oxysterol 7a-hydroxylase defect
Biochemical measurement of 7a-hydroxylase activity. Choles-
terol 7a-hydroxylase enzyme activity was not detectable in nor-
mal liver tissue from infants of , 1 yr of age, or in the patientÕs
liver. The absence of this activity was consistent with the lack of
7a-hydroxycholesterol in the serum and urine of this individual
and with earlier published studies (45). 7a-Hydroxylated 25-
hydroxycholesterol was formed by membranes prepared from
1-, 2-, and 6-mo control livers (sp act 5 1.4—1.8 pmol/min/mg
protein), whereas there was no detectable oxysterol 7a-hydrox-
ylase activity in the patientÕs liver (Fig. 9). All specimens con-
tained equal amounts of steroid 5a-reductase type 1 enzyme ac-
tivity (Fig. 9), a marker enzyme for tissue viability.
Molecular analyses of 7a-hydroxylase genes. The biochemi-
cal data were consistent with a defect in either the cholesterol
7a-hydroxylase gene (symbol CYP7A1) or the oxysterol 7a-
hydroxylase gene (symbol CYP7B1). To resolve this dichot-
omy, both genes were screened for the presence of inactivating
mutations. The cholesterol 7a-hydroxylase gene has been
characterized previously and oligonucleotide primers for the
amplification and analysis of individual exons of the gene have
been reported (46). Analysis of the six exons of CYP7A1 in the
probandÕs DNA by SSCP and DNA sequencing did not reveal
any mutations in the coding region of the gene, suggesting that
the underlying defect in this patient was not due to mutation of
the cholesterol 7a-hydroxylase gene.
Oxysterol 7a-hydroxylase cDNAs encoding the rat and
mouse enzymes have been reported (47); however, a cDNA
for the human homologue had not been isolated, nor had the
exon-intron structure of the gene or its chromosomal location
been determined. To these ends, human oxysterol 7a-hydroxy-
lase cDNAs were isolated with a two-step strategy. Initially,
degenerate primers from the mouse cDNA sequence were
used to isolate a fragment of the human cDNA by RT-PCR us-
ing 293 cell mRNA as a template. This fragment was then used
as a probe to screen commercially available human cDNA
libraries to isolate a full-length copy of the mRNA. DNA se-
quence analysis and conceptual translation revealed a 506—
amino acid human oxysterol 7a-hydroxylase (Fig. 10). The en-
coded protein is 66% and 65% identical in sequence to the
mouse and rat enzymes, respectively. Transfection of the hu-
man cDNA into 293 cells resulted in a threefold increase over
background of oxysterol 7a-hydroxylase enzyme activity when
25-hydroxycholesterol or dehydroepiandrosterone was used as
a substrate (data not shown). The 7a-hydroxylated steroids
from these reactions comigrated in two different solvent sys-
tems with the products synthesized from these substrates by an
expressed murine oxysterol 7a-hydroxylase whose chemical
identities were confirmed (21, 22). The shared sequence identi-
ties, enzymatic properties, and gene structure and linkage (see
below) indicated that the isolated human cDNA encoded a ho-
mologue of the rodent oxysterol 7a-hydroxylase.
Figure 8. The effect of cholic 
acid therapy (15 mg/kg body wt/d) 
on the concentrations of 3b-
hydroxy-5-cholenoic and 3b-
hydroxy-5-cholestenoic acid in 
the serum and urine from a pa-
tient with an oxysterol 7a-
hydroxylase deficiency. The 
histogram depicts the concentra-
tions of the exogenous cholic 
acid administered.
Figure 9. Measurement 
of oxysterol 7a-hydrox-
ylase and steroid 5a-
reductase type 1 activity 
in liver membranes. Mi-
crosomal membrane 
proteins (250 mg) were 
incubated with [3H]25-
hydroxycholesterol (A) 
or [14C]testosterone (B) 
and the conversions of 
these substrates into 
[3H]cholest-5-ene-
3b,7a,25-triol and 
[14C]dihydrotestoster-
one, respectively, were 
determined in dupli-
cate by thin layer chro-
matography. The mean 
activities derived from 
two experiments are 
shown. Oxysterol 7a-
hydroxylase activity was detected in the control samples from individ-
uals of age 1, 2, and 6 mo, but not in the patientÕs liver (A). All samples 
contained similar amounts of steroid 5a-reductase type 1 activity (B).
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Screening of bacteriophage lambda libraries produced the
human CYP7B1 gene. Southern blotting and DNA sequence
analysis of the genomic DNA and comparison to the cDNA
revealed a gene composed of six exons (Fig. 10). The positions
of the five introns were identical to those of the cholesterol 7a-
hydroxylase gene. Both genes were positioned on the human
chromosome complement by PCR analysis of radiation hybrid
panel DNAs. In agreement with previous mapping data (46),
CYP7A1 was localized to chromosome 8q21.13, closely linked
(LOD score 5 1,000) to the D8S1113 marker. Additional ex-
periments showed that CYP7B1 was localized to chromosome
8q21.3, closely linked (LOD score 5 9.7, cR value 5 21.12) to
the D8S1473 marker. The close linkage of the genes encoding
cholesterol and oxysterol 7a-hydroxylase and their shared
exon-intron structures suggest that they arose via an ancient
duplication event.
To screen for mutations in the patientÕs oxysterol 7a-
hydroxylase gene, oligonucleotide pairs were used to amplify
individual exons. Each DNA was then subjected to DNA se-
quence analysis. As shown in Fig. 11, the patient was homozy-
gous for a cytosine to thymidine transition mutation in exon 5
that converted an arginine codon at position 388 to a nonsense
codon (R388*). His mother (Fig. 11) and father (not shown)
were heterozygous for this nonsense mutation. The R388* mu-
tation was not detected in 16 unrelated healthy Mexican sub-
jects and has not been found in any other control DNAs.
To confirm that the nonsense mutation abolished oxysterol
7a-hydroxylase enzyme activity, the mutation was reproduced
in an expressible mouse cDNA using site-directed mutagene-
sis. The mouse oxysterol 7a-hydroxylase was used in these ex-
periments due to the availability of an antibody against the
murine protein (22). Transfection of the normal murine cDNA
into 293 cells produced easily detectable oxysterol 7a-hydroxy-
lase enzyme activity, whereas no activity was present in cells
transfected with the cDNA containing the R388* mutation
(Fig. 12). Immunoblot analysis showed that equal amounts of
normal and truncated protein were present in the transfected
cells (Fig. 12, inset). Similar results were obtained when the
normal and mutant cDNAs were analyzed by transfection in
Chinese hamster ovary cells (data not shown).
Discussion
Mammals dispose of cholesterol principally by converting it
into 7a-hydroxylated bile acids that are secreted in the bile
(10). The classical pathway of bile acid synthesis is initiated by
Figure 10. Molecular analysis of the oxysterol 7a-hydroxylase gene. 
The amino acid sequence of the enzyme as deduced from translation 
of the cDNA is shown in a single letter code. Amino acids are num-
bered on the right with position 1 assigned to the initiator methio-
nine. An asterisk marks the location of the mutation at residue 388. 
The accession number for the cDNA sequence is AF029403. The pre-
dicted structure of CYP7B1 is shown with exons indicated by boxes 
and introns by connecting lines. Exons are assigned Roman numerals 
and drawn to scale. The 59- and 39-flanking regions of the gene and 
the introns are not drawn to scale. Amino acids encoded by individ-
ual exons are indicated above the boxes.
Figure 11. Amplification and sequencing by the dideoxyterminator 
method of exon 5 of the oxysterol 7a-hydroxylase gene from the ge-
nomic DNAs of the patient and his mother. A transition mutation 
(Cfi T) producing a premature termination codon (R388fi Stop) is 
present in the heterozygous form in the mother (left) and in the ho-
mozygous form in the patient (right). The mutation occurred in a CG 
dinucleotide.
Figure 12. Expression of the normal and mutant oxysterol 7a-hydrox-
ylases. cDNAs encoding the normal murine cDNA or a version carry-
ing the R388Stop mutation were inserted into a pCMV expression 
vector and transfected into 293 cells. The ability of the expressed pro-
teins to convert [3H]25-hydroxycholesterol into 7a,25-dihydroxycho-
lesterol was monitored by thin layer chromatography and expressed 
as a function of the incubation time. The levels of normal and mutant 
proteins present in the transfected cells after a 1.5-h incubation were 
determined by immunoblotting (inset).
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cholesterol 7a-hydroxylase (EC 1.14.13.17), a cytochrome
P-450 enzyme of liver microsomes (48) (Fig. 13). The resultant
7a-hydroxycholesterol undergoes further hydroxylations and
oxidoreduction, followed by side-chain cleavage to form the
primary bile acids, cholic and chenodeoxycholic acids (10). An
alternative pathway, referred to as the acidic pathway (14—20),
has been described in which cholesterol is first hydroxylated in
the side chain by a mitochondrial sterol 27-hydroxylase (EC
1.14.13.15) that is also localized in extrahepatic tissues includ-
ing, brain (49, 50), arterial endothelium (51), and fibroblasts
(52), and the product, 27-hydroxycholesterol, is further hydrox-
ylated at the C-7a position by an oxysterol 7a-hydroxylase that
resembles, but is distinct from, the cholesterol 7a-hydroxylase
of the classical pathway (16, 18, 22, 53). In mice, the physio-
logic relevance of the alternative pathway was established by
the finding that adult mice homozygous for a knockout of the
cholesterol 7a-hydroxylase gene produced 7a-hydroxylated bile
acids, apparently as a result of this alternative pathway (21). In
the rat, under conditions of complete repression of cholesterol
7a-hydroxylase by continuous infusion of squalestatin, bile
acid synthesis after 24 h was still 43% of preinfusion levels, in-
dicating that the alternative pathway may account for almost
half of the total bile acid synthesis (20). Precursor studies in
humans indicate that the acidic pathway synthesizes z 50% of
the total bile acids (14). In adult patients with liver diseases,
when bile acid synthesis is reduced (54—57), concentrations of
cholestenoic acids are elevated (58), which also suggests that
the alternative pathway is a significant contributor to bile acid
synthesis in humans.
Here, we describe an infant with severe neonatal cholesta-
sis whose biological fluids were virtually devoid of 7a-hydrox-
ylated bile acids due to a mutation in the gene encoding oxy-
sterol 7a-hydroxylase. In addition to establishing a further
inborn error in bile acid synthesis as a cause of cholestatic liver
disease, these observations demonstrate the quantitative im-
portance of the acidic pathway for bile acid synthesis in human
fetal and neonatal life. The infant, a 10-wk-old Mexican off-
spring of a first cousin marriage presented with progressive
jaundice, elevated concentrations of serum liver enzymes, and
a prolonged prothrombin time due in part to vitamin K malab-
sorption. Interestingly, there was a normal serum g-glutamyl-
transpeptidase concentration, which has been shown previ-
ously to be highly associated with, although not exclusive to,
patients with inborn errors in bile acid synthesis (59), since it is
also a feature of BylerÕs disease, a condition of progressive fa-
milial intrahepatic cholestasis (60—62). A liver biopsy and
histological analysis revealed diffuse syncytial giant cell trans-
formation of hepatocytes with associated bile ductule prolifer-
ation and fibrosis (Fig. 2) and the histologic appearance resem-
bled that observed in other inborn errors in bile acid synthesis
(3, 4, 11, 63).
The diagnosis of a specific defect in 7a-hydroxylation was
established by FAB-MS analysis of the urine, which revealed a
mass spectrum characterized by the absence of the normal pri-
mary bile acid conjugates and the presence of a series of un-
usual bile acids having molecular weights characteristic of un-
saturated monohydroxylated bile acid conjugates. These were
confirmed by GC-MS analysis to be monohydroxy bile acids
with a 3b-hydroxy-D5 structure, and in common with most ste-
roids with this nuclear structure, these metabolites are prefer-
entially sulfated in the liver (64, 65). The 3b-hydroxy-D5 bile
acids constituted . 90% of the serum bile acids and . 75% of
the urinary bile acids. These metabolites also accounted for
24% of the liver tissue bile acids even during exogenous cholic
acid therapy (Table I). 3b-Hydroxy-5-cholenoic acid is a nor-
mal constituent of amniotic fluid (66, 67) and meconium (68)
and is found in small proportions in normal adult urine (32).
However, it is increased in the urine of infants with cholestatic
liver disease (35, 69), although not to the extent observed in
the patient reported here; furthermore, in contrast to our pa-
tient, high concentrations of cholic and chenodeoxycholic ac-
ids accompany the elevations in 3b-hydroxy-5-cholenoic acid.
3b-Hydroxy-5-cholenoic acid was also found in low concentra-
tions in the urine, but not the serum of the parents, who both
showed serum and urinary bile acid profiles that were similar
to those of healthy adults.
The mechanism of liver injury in this patient is proposed to
be due to the accumulation of high concentrations of hepato-
Figure 13. The two major path-
ways for primary bile acid syn-
thesis from cholesterol depicting 
the biochemical presentation of
a deficiency in oxysterol 7a-
hydroxylase as a cause of severe 
neonatal cholestatic liver disease.
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toxic monohydroxy bile acids with the 3b-hydroxy-D5 structure
(70). The cholestatic effects of these metabolites would be fur-
ther exacerbated by the lack of primary bile acids, which
would normally provide the essential driving force for bile
flow. It has been demonstrated that the taurine conjugate of
the dihydroxy bile acid, 3b,7a-dihydroxy-5-cholenoic acid, a
major bile acid synthesized by patients with liver disease due
to a deficiency in 3b-hydroxy-C27-steroid dehydrogenase/
isomerase (3), is not transported in an ATP-dependent man-
ner, and that it also inhibits the ATP-dependent transport of
cholic acid across rat canalicular plasma membranes (71). The
monohydroxy bile acid, tauro-3b-hydroxy-5-cholenoic acid, is
markedly cholestatic in the rat, reducing bile flow and choles-
terol and phospholipid secretion in a dose-dependent manner
(70, 72). It was shown to have an even greater cholestatic po-
tency than its saturated analogue, taurolithocholic acid (72).
The accumulation of monohydroxy bile acids may also injure
the liver through the generation of oxidant stress (73). Con-
trary to the general assumption that sulfation of bile acids
provides a protective mechanism against cholestasis, tauro-3b-
hydroxy-5-cholenoate sulfate proved still to be markedly chole-
static in the rat, albeit with a less pronounced effect than that
seen with the nonsulfated analogue (72). The accumulation of
3b-hydroxy-D5 cholenoic and cholestenoic acids in the liver of
this patient could also contribute to reduced cholic acid synthe-
sis via downregulation of the classical pathway using choles-
terol 7a-hydroxylase. In this regard, infusion of 3b-hydroxy-D5-
cholenoic acid reduces cholic acid synthesis in the rabbit (74).
Analysis of neutral sterol fractions of serum and urine from
the patient revealed GC profiles that featured a prominence
of a major oxysterol, identified by mass spectrometry as 27-
hydroxycholesterol; concentrations in serum (314 mg/ml or 781
mmol/liter) were found to be . 4,500-fold those reported for
the mean values in normal adult serum (39, 75—79). In addi-
tion, evidence for other side chain hydroxylated sterols was
obtained by mass spectrometry, including elevated concentra-
tions of 24-hydroxycholesterol, whereas 7a-hydroxycholes-
terol could not be identified in any of the samples analyzed.
The lack of 7a-hydroxylated bile acids and sterols implies a de-
ficiency in the activity of either cholesterol 7a-hydroxylase or
oxysterol 7a-hydroxylase (Fig. 13) and the biochemical pre-
sentation is consistent with a metabolic defect involving the
latter enzyme, since 3b-hydroxy-5-cholenoic and 3b-hydroxy-
5-cholestenoic acids can only be formed via the acidic pathway
(Fig. 13), neither being good substrates for cholesterol 7a-
hydroxylase (16). These intermediates would normally be
hydroxylated by the oxysterol 7a-hydroxylase to ultimately
form chenodeoxycholic acid (80), although in the hamster they
are less favorable substrates than 27-hydroxycholesterol for
this enzyme (81). Interestingly, in this patient, the chenode-
oxycholic acid concentration was only 6% of the level observed
in normal human adult liver tissue (82). An oxysterol 7a-hydrox-
ylase defect is additionally supported by the finding of vast
concentrations in serum and urine of 24-hydroxycholesterol,
25-hydroxycholesterol, and 27-hydroxycholesterol (Table II)
which are substrates for oxysterol 7a-hydroxylase. Given this
biochemical and molecular presentation, this conclusion would
imply that, in contrast to the mouse (21, 22), bile acid synthesis
in early human development proceeds mainly via the acidic
pathway and that cholesterol 7a-hydroxylase is quantitatively
of less importance in the human neonate. This interpretation
would also explain the high concentration of 3b-hydroxy-
5-cholenoic acid in amniotic fluid (66, 67) and meconium (68),
and the predominance of chenodeoxycholic acid in human fe-
tal bile (83, 84). As such, it is reasonable to assume that there
may be species differences in the developmental expression of
the two enzymes.
Measurements of hepatic 7a-hydroxylase enzyme activities
provided support for a defect in the oxysterol 7a-hydroxylase.
Thus, while no oxysterol 7a-hydroxylase activity was detected
in membranes isolated from the patientÕs liver, control livers
from infants all had measurable activity of this enzyme (Fig. 9).
Interestingly, cholesterol 7a-hydroxylase activity was not de-
tected in the liver samples from infants of , 1 yr of age, includ-
ing the patientÕs liver. This finding is supported by previous re-
ports showing that cholesterol 7a-hydroxylase enzyme activity
is low to undetectable in human infant liver (45, 85). While a
loss of cholesterol 7a-hydroxylase enzyme activity might ex-
plain the lack of 7a-hydroxylated bile acids, it would not ac-
count for the predominance of the 3b-hydroxy-D5 bile acids or
the 27-hydroxycholesterol in this patient.
Unambiguous identification of the inborn error in bile acid
synthesis in the patient subsequently came from molecular
cloning studies which revealed a normal cholesterol 7a-hydrox-
ylase gene and a nonsense mutation (R388*) in the fifth exon
of the oxysterol 7a-hydroxylase gene (Fig. 10). This mutation
was only detected in the patient and his parents. Truncation of
the protein at this location is predicted to remove an essential
cysteine residue (amino acid 449 in the normal protein, Fig. 10)
that is conserved in all cytochrome P-450 enzymes and that
normally forms a covalent bond with the essential heme cofac-
tor (86). As expected, the truncated oxysterol 7a-hydroxylase
protein was inactive when expressed in cultured cells (Fig. 12).
Overall, these results demonstrate the importance of the
oxysterol 7a-hydroxylase enzyme to fetal and neonatal bile
acid synthesis. A deficiency in the synthesis of 7a-hydroxylated
bile acids occurs in the neonatal period when this enzyme is
absent, despite the presence of an apparently normal gene for
cholesterol 7a-hydroxylase. Failure to express cholesterol 7a-
hydroxylase activity could be explained by some translational
or posttranslational problem associated with the accumulation
of large concentrations of oxysterols resulting from the mu-
tation in the oxysterol 7a-hydroxylase gene. Oxysterol 7a-
hydroxylase deficiency thus represents a further inborn error
in bile acid synthesis causing progressive neonatal intrahepatic
cholestasis. More than 2,500 samples from cholestatic infants
have been analyzed by mass spectrometry during the last 10 yr
in Cincinnati, and this is the first patient identified with a defi-
ciency in 7a-hydroxylation of bile acids. Given the relatively
early age of the patient and the severity of the liver disease, it
is possible that a mutation in the oxysterol 7a-hydroxylase
gene causes prenatal or early neonatal lethality, and that this
case represents an exception to fetal death. However, with
more widespread screening by mass spectrometry of neonates
with advanced liver disease it is possible that the disorder may
be more prevalent than the clinical screening has indicated so
far. Clearly it is apparent that the oxysterol 7a-hydroxylase is
an important enzyme for protecting the liver from the toxicity
of monohydroxy-bile acids synthesized exclusively through the
acidic pathway (Fig. 13) as was proposed some years ago by
Javitt (80), while it probably represents an important pathway
for the regulation of cholesterol homeostasis (19, 49, 52, 87).
The prognosis for patients with an oxysterol 7a-hydroxy-
lase deficiency appears poor relative to those with other in-
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born errors in bile acid synthesis. Oral primary bile acid ther-
apy, which has led to normalization in liver function and
histology in most patients with liver disease due to deficiencies
in 3b-hydroxy-C27-steroid dehydrogenase/isomerase (3) and
D4-3-oxosteroid 5b-reductase (4), proved ineffective in this pa-
tient. Cholic acid administration in the previously described
bile acid defects downregulates endogenous bile acid synthe-
sis, leading to a virtual disappearance of the atypical hepato-
toxic metabolites concomitant with clinical improvement (1, 2,
11, 12). This biochemical response did not occur in this patient,
consistent with a lack in 7a-hydroxylase activity and suggesting
that cholic acid normally downregulates the expression of this
gene (21). Consequently, it would appear that orthotopic liver
transplantation may be the only therapeutic modality in the
face of advancing liver disease due to hepatotoxicity from the
accumulation of monohydroxy 3b-hydroxy-D5 bile acids pro-
duced as a consequence of the genetic defect in oxysterol 7a-
hydroxylase.
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